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speciﬁc quality criteria developed by the authors. RESULTS: We
found 45 comparative studies in 43 publications. Asthma (14
studies) and psychiatric illness (12 studies) were most commonly
investigated. In 33 studies, interventions were educational, 20
had multiple components and 23 did not appear to be linked to
proven reasons for non-adherence. No studies assessed manage-
ment of unintentional non-adherence. No study met all quality
criteria. Study quality has not improved with time, as some better
studies are over ten years old. Many studies used inadequate or
unidentiﬁable adherence measures. Critically, many were too
small or not randomised. All studies assumed that patients were
prescribed appropriate therapy for their condition, and no
assessment of treatment quality was made by any study. Report-
ing of adherence and outcome results was often unclear. Cost
data were poorer quality than outcome data, using average or
estimated costs and omitting some cost elements. Nine studies
carried out incremental economic analysis. CONCLUSIONS:
We were not able to make deﬁnitive conclusions about the cost-
effectiveness of medication adherence enhancing interventions
due to the heterogeneity of the studies found and incomplete
reporting of results. Important policy decisions need to be made
about non-adherence, however, they are currently being made in
a vacuum of adequate information. Medication adherence-
enhancing interventions must be based on reasons for non-
adherence and be evaluated using accepted clinical and economic
quality criteria.
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OBJECTIVES: To study medication compliance patterns regard-
ing dosing, timing and adherence under real life conditions.
Using a new electronic blister pack system. METHODS: A total
of 37 volunteers from three study centers were each furnished
with an electronic blister holder (“monitor”) and three blister
packs containing 14 placebo capsules each (trial duration: six-
weeks). The monitor measured the disruption of conductive lines
printed on aluminum carrier foil under each capsule and stored
this information (date and time) for evaluation at the end of the
study. Patients had to take out one capsule daily in the morning
over the entire study period. Also patients received a CRF and a
radio-controlled clock such that date and time of the event could
be manually recorded by the patient as well. Data were consid-
ered accurate if the information stored in the monitor and the
corresponding CRF entries were within a time window of ±15
min. RESULTS: All recordings of the electronically stored infor-
mation matched the data documented on the CRFs. This indi-
cates the accurate documentation of the volunteers, as well as
the correct functioning of the monitors. Evaluation of the data,
however, showed a wide intra—as well as interindividual varia-
tion in the time patterns of the volunteers. Three clusters of 
time preference were detected—mornings, noon and late night.
Further, periods of non-compliance (“drug holidays”) as well as
lack of adherence (discontinuation of medication before the end
of the study period of six-weeks) could be documented. CON-
CLUSIONS: The use of the new electronic blister system
improves compliance measurement under real life conditions.
Combining compliance information with other outcome para-
meters will help in better quantifying and optimizing the impact
of patient compliance on clinical and economic outcomes under
real life conditions.
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OBJECTIVE: Chronic disease sufferers are particularly affected
by prescription copayment increases as they are faced with deci-
sions to switch to formulary alternatives or pay more to stay on
their current medication. The objective of this study was to eval-
uate the impact of increased prescription copayments as a result
of a change in formulary status on continuation rates of non 
formulary medications in multi-tiered pharmacy beneﬁt plans.
METHODS: Retrospective cohort study of chronic disease
patients from a health plan in the Western U.S. Individuals were
selected who were taking a medication that was being removed
from the health plan’s formulary and thus experienced increases
in their copayments for non formulary medications (n = 1244).
Two time periods were studied: the “pre” period before and the
“post” period after the increase in copayments. Adjusting for
demographics, chronic co-morbidities, medication use, Medicare
+ Choice status and percentage increase in copayment for non
formulary medications, Cox regressions were used to assess 
continuation rates for these medications. RESULTS: A clear 
relationship between increasing copayment differentials and con-
tinuation rates for non formulary medications in the post period
could not be established. In general those who experienced
higher copayment differentials (between 50–100%, 100–200%
and greater than 200%) were more likely to continue their non
formulary medication than those who experienced copayment
increases of 25–50% and less than 25%. CONCLUSIONS: Indi-
viduals confronted with increased copayments often switched
their medications to formulary alternatives. However, a clear
relationship could not be established between increasing copay-
ments and continuation behavior. Further research is needed to
determine if these switching behaviors results in inappropriate
medication behaviors such as complete discontinuation of drug
therapy due to the increased costs.
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OBJECTIVES: The economics theory of consumer behavior sug-
gests that the impact of cost on product purchasing decisions
depends on the perceived beneﬁts associated with that product.
However, this relationship has been neither demonstrated nor
quantiﬁed for patients taking chronic medications. The objective
of this study was thus to analyze the impact of cost on medica-
tion compliance (reﬁlls) among groups of individuals with dif-
ferent levels of perceived beneﬁts. METHODS: Patients new to
statin therapy were identiﬁed from the prescription database of
a national retail chain. The perceived beneﬁt of the statin med-
ication was measured on a scale of one (low) to seven (high) by
surveying randomly selected new patients. Compliance with the
medication regimen during the ﬁrst 12 months of statin therapy
was measured in terms of the Medication Possession Ratio
(MPR). Information on cost and (MPR) on randomly selected
patients was obtained from the retail chain prescription data-
